Anthropic is stepping beyond its core business and founding its own drug development program. The company plans to research treatments for neglected diseases that the traditional pharmaceutical industry considers economically unprofitable. The initiative launches with a focus on early, preclinical-stage drug discovery – while simultaneously sharpening Anthropic's AI models.
The essentials
- Anthropic launches drug discovery program for diseases pharma companies ignore
- Novartis CEO Vas Narasimhan expects AI to cut development time from 12 to 7–8 years and double success rates from 8 to 16 percent
- Claude Science identified viral contamination in minutes that a UCSF team missed for an entire year
- Competitors Google DeepMind (Isomorphic Labs) and OpenAI (ChatGPT Health) are also pushing into medicine
Where AI saves time – and where it doesn't
The hope is high, but realistic: Narasimhan breaks the 12-year development cycle into three components. Information latency, operational latency, and biological latency – and only the first two can be significantly reduced by AI.
| Factor | Share | AI Potential |
|---|---|---|
| Information & operational latency | ~40 % | High |
| Biological latency (testing, clinical trials) | ~60 % | Low |
Biological latency – animal testing, cell models, human clinical trials – cannot be easily accelerated. That's why Narasimhan expects a reduction to 7–8 years, not less.
Claude finds patterns in minutes
Anthropic's Claude Science tool is already showing results: a UCSF researcher used it to detect viral contamination in minutes – something his team had missed for an entire year. In another test, Claude analyzed 100 rare genetic diseases in under an hour and identified 32 candidates for further computational screening.
These examples illustrate what Anthropic is after: spotting patterns humans miss. Especially for rare and neglected diseases, where research is sparse, this could be decisive.
The race for AI in medicine
Anthropic's move is part of a larger trend. Google DeepMind co-founded Isomorphic Labs to apply AI directly to drug discovery. AlphaFold, DeepMind's protein structure prediction tool, remains one of the most prominent examples of AI in biology. OpenAI is also moving into healthcare – with initiatives like ChatGPT Health.
Notably: John Jumper, co-developer of AlphaFold, recently joined Anthropic. A signal that talent is flowing between AI labs.
What this means for German companies
For German pharma and biotech firms, a paradigm shift is underway. AI labs like Anthropic now compete not just for attention, but for drug pipelines. Companies researching rare diseases or holding data infrastructure could become partners or acquisition targets. At the same time, a question emerges: Can traditional pharma keep pace with AI-native companies on speed – or do new collaboration models emerge? The coming years will show whether Anthropic's approach – advancing AI through real drug discovery – actually accelerates the path to medicines.
Sources
Editorially owned by Ideal Syka. Sources and method: Newsroom & method. Tips and corrections: ai@i6eal.de.
